Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin Versus Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin in the Management of Hepatitis C Patients Fauilre to Prior Sofosbuvir/ Daclatasvir (An Open-labeled Randomized Trial)
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Daclatasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2018 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 08 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 08 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.